We are live on ! Find out more
NM

Newtyn Management Portfolio holdings

AUM $936M
1-Year Est. Return 27.23%
This Fund
S&P 500
This Quarter Est. Return
-7.05%
1 Year Est. Return
+27.23%
3 Year Est. Return
+51.99%
5 Year Est. Return
+55.23%
10 Year Est. Return
+165.15%
AUM
$533M
AUM Growth
+$30.6M
Cap. Flow
+$69.5M
Cap. Flow %
13.05%
Top 10 Hldgs %
65.84%
Holding
49
New
9
Increased
10
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$45.6M
2
SOLV icon
Solventum
SOLV
+$42.5M
3
BV icon
BrightView Holdings
BV
+$22.3M
4
FSP
Franklin Street Properties
FSP
+$13.5M
5
TSVT
2seventy bio
TSVT
+$11.2M

Top Sells

Rank Stock Value
1
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$27.7M
2
CNNE icon
Cannae Holdings
CNNE
+$25.9M
3
MITK icon
Mitek Systems
MITK
+$12.3M
4
PAR icon
PAR Technology
PAR
+$12M
5
CDMO
Avid Bioservices, Inc. Common Stock
CDMO
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 30.47%
2 Communication Services 18.1%
3 Real Estate 13.17%
4 Technology 12.06%
5 Energy 6.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
26
Wave Life Sciences
WVE
$1.14B
$2.37M 0.45%
475,000
-25,000
-5% -$143K
MITK icon
27
Mitek Systems
MITK
$768M
$2.23M 0.42%
199,698
-958,865
-83% -$12.3M
KOD icon
28
Kodiak Sciences
KOD
$2.62B
$2.19M 0.41%
930,000
-70,000
-7% -$237K
ETNB
29
DELISTED
89bio
ETNB
$1.92M 0.36%
240,000
-10,000
-4% -$89.3K
MURA
30
DELISTED
Mural Oncology
MURA
$1.79M 0.34%
570,000
+70,000
+14% +$258K
ABEO icon
31
Abeona Therapeutics
ABEO
$349M
$1.61M 0.3%
+380,000
New +$1.94M
OLMA icon
32
Olema Pharmaceuticals
OLMA
$1.05B
$1.51M 0.28%
140,000
-10,000
-7% -$108K
AVIR icon
33
Atea Pharmaceuticals
AVIR
$386M
$1.26M 0.24%
380,000
-20,000
-5% -$74.6K
BOLT icon
34
Bolt Biotherapeutics
BOLT
$7.63M
$1.02M 0.19%
68,162
-16,838
-20% -$332K
GRAL
35
GRAIL Inc
GRAL
$2.87B
$527K 0.1%
+34,269
New +$556K
BDTX icon
36
Black Diamond Therapeutics
BDTX
$99.1M
$443K 0.08%
95,000
-30,000
-24% -$161K
FET icon
37
Forum Energy Technologies
FET
$640M
$253K 0.05%
15,000
-179,300
-92% -$3.3M
ALGS icon
38
Aligos Therapeutics
ALGS
$25.2M
$252K 0.05%
28,771
-19,229
-40% -$338K
LFLYW
39
DELISTED
Leafly Holdings, Inc. Warrant
LFLYW
$9.84K ﹤0.01%
634,640
– –
ADPT icon
40
Adaptive Biotechnologies
ADPT
$3.61B
– –
-623,690
Closed -$2M
ADVM
41
DELISTED
Adverum Biotechnologies
ADVM
– –
-46,189
Closed -$653K
ASTL icon
42
Algoma Steel
ASTL
$463M
– –
-590,899
Closed -$5.02M
PHAT icon
43
Phathom Pharmaceuticals
PHAT
$953M
– –
-165,000
Closed -$1.75M
FTH
44
Faeth Therapeutics
FTH
$754M
– –
-46,512
Closed -$977K
VNDA icon
45
Vanda Pharmaceuticals
VNDA
$314M
– –
-311,000
Closed -$1.28M
TECX
46
Tectonic Therapeutic
TECX
$578M
– –
-93,241
Closed -$1.43M
CDMO
47
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
– –
-1,500,000
Closed -$10.1M
MACK
48
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-1,873,694
Closed -$27.7M
1
2

Similar funds

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Newtyn Management's Q2 2024 Portfolio in Review

As of Q2 2024, Newtyn Management held 49 positions worth $533M, up 6.1% from $502M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Newtyn Management deployed $69.5M of net new capital in Q2 2024, opening 9 new positions and adding to 10 existing holdings. Its largest new stake was QuidelOrtho: 1,115,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 22% a quarter earlier, followed by Communication Services and Real Estate.

On the sell side, the largest reduction was Cannae Holdings, an estimated $25.9M trimmed.

  • Newtyn Management's largest Q2 2024 buy was QuidelOrtho: 1,115,000 shares worth $37M.
  • Newtyn Management added most to Cogent Communications in Q2 2024, an estimated $8.95M increase.
  • Newtyn Management's biggest Q2 2024 reduction was Cannae Holdings, cutting an estimated $25.9M.
  • Newtyn Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $27.7M.
  • Newtyn Management's ten largest holdings make up 66% of its $533M portfolio in Q2 2024.
  • Newtyn Management opened 9 new positions and closed 9 in Q2 2024.
  • Newtyn Management's portfolio value rose 6.1% quarter-over-quarter to $533M.

Based on Newtyn Management's 13F filing for Q2 2024, filed 14 Aug 2024.